Sanofi enters three-year collaboration with Stanford Medicine to advance immunology research
Paris: Sanofi has recently announced that the company has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the two organizations and their scientists will work to advance the understanding of immunology and inflammation through open scientific exchange.
Additionally, Sanofi will provide funding and scientific inputs into projects of mutual interest, crossing multiple therapeutic areas including autoimmune diseases and inflammatory conditions.
- Exploring cytokine crosstalk in type 2 inflammation, specifically examining the impact of Sanofi's investigational molecules on excessive type 2 inflammation.
- Decoding molecular drivers of effector and suppressor T cells in autoimmunity, to better understand the specific antigens that may cause type 1 diabetes.
- Defining the mechanisms of immune-related adverse events with immune checkpoint inhibitor therapy – with a focus on pneumonitis and inflammatory arthritis – to explore the role of genomics and pathogenic cell identification.